Answers are grounded in this paper and cite their sources.
Background. Pre-licensure and post implementation pneumococcal conjugate vaccine (PCV) studies have demonstrated that PCV impact on recurrent, non-responsive and chronic OM cases (complex-OM; COMP-OM) was significantly larger (up to 40%) than when all-cause OM or first OM were measured. COMP-OM is frequently caused by non-pneumococcal pathogens, often forming biofilm, in which non-typable Haemophilus influenzae (NTHi) is the most frequent. We assessed the impact of PCV7/PCV13 introduction on all-cause COMP-OM enriched OM episodes, as well as specifically pneumococcal, NTHi and culture-negative episodes. Methods. These were previously described (Dagan et al, 49th IDSA, Abstr. 1344, 2012). The surveillance period was July 2004 through December 2013. PCV7 was introduced to the National Immunization Program (NIP; with catch-up) in July 2009 and has been gradually replaced by PCV13 since November 2010. Results. Overall, 6,250 OM episodes for which information was available, were submitted for culture. ≥1 factors associated with COMP-OM were present in 2685/3996 (67%) children: 2165/3331 (65%) in culture-positive children and 520/665 (78%) in culture-negative patients. Incidences (per 1,000 children <2 years) of PCV7 + 6A serotypes, serotypes 1, 3, 5, 7F, 19A, non-PCV13 serotypes and overall pneumococcal OM by 6 month-intervals and rate reduction calculations are shown in Figure 1. Incidences of NTHi, culture-negative and all-cause OM as well as rate reduction calculations are shown in Figure 2. Conclusion. All OM cases, including pneumococcal, NTHi and culture-negative episodes enriched with COMP-OM were markedly reduced in children <2 years after PCV7/PCV13 introduction. Disclosures. R. Dagan, Pfizer: Consultant, Grant Investigator, Scientific Advisor and Speaker's Bureau, Consulting fee, Research grant and Speaker honorarium; MSD: Consultant, Grant Investigator and Scientific Advisor, Consulting fee and Research grant; GSK: Consultant and Speaker's Bureau, Consulting fee and Speaker honorarium E. Leibovitz, Pfizer: Speaker's Bureau, Speaker honorarium
No takes yet. Share an insight, caveat, or question.
Dagan et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: